ERBB2 and neoplasm: Radziuviene et al. [33] also reported that the variance in CD8 density along the tumor edge is an independent predictor of OS in IHC HER2-borderline breast cancer without HER2 amplification; however, high CD8+ SD was associated with shorter OS in this patient cohort.